The Day After Schedule III: What Cannabis Executives Need To Prepare For Now

Moving medical cannabis from Schedule I to Schedule III marked the most significant federal cannabis reform in more than 50 years. It also created a complicated new reality for operators, regulators, and investors.

That tension shaped the discussion during “Beyond the Announcement: Understanding Federal Cannabis Rescheduling” at the IgniteIt Cannabis Capital Conference in Chicago. Moderator Saphira Galoob joined federal policy specialist David Mangone and former Nevada cannabis regulator Tyler Klimas to examine what the federal order accomplished, what it left unresolved, and what operators should be doing while agencies develop the rules needed to implement it.

The panel’s central message was straightforward: Schedule III is a major shift, but it is only the beginning.

The Federal Government Deferred To State Medical Programs

Mangone began with an underreported provision in the federal order: a severability clause indicating that if one portion is found invalid or unconstitutional, the government intends for the remainder to survive.

That language matters because rescheduling is already facing administrative proceedings and litigation. It may give the government a way to preserve portions of the framework even if a court rejects another section.

The order also could have imposed a narrow federal definition of qualifying medical cannabis. The attorney general could have limited eligibility by product type, approved provider, or qualifying condition. Instead, the government largely deferred to state medical programs.

That means medical cannabis licensed under Georgia’s more restrictive system could receive the same federal scheduling treatment as products licensed under a more permissive program such as California’s.

For Mangone, that decision represented significant federal recognition of the regulatory work states have completed over the past decade.

“The fact that there’s no really unique and specific guardrails that were identified in this order really shows that this Department of Justice is willing to put a lot of trust and put a lot of faith into the work that the states have done.”

It also established a broader policy precedent: two successive administrations have now recognized cannabis’ medical value and concluded that Schedule I was the wrong classification.

Dual-Licensing Systems Could Create Administrative Headaches

Federal deference to state programs does not mean those systems will integrate smoothly with the DEA.

Klimas explained that state regulators built their markets without a federal blueprint. Over more than a decade, they combined licenses, inventory systems, and administrative functions to reduce costs and make regulation more efficient.

Those efficiencies may now create complications.

Maryland, for example, allows medical and adult-use inventory to remain together until the point of sale. The same cultivation or retail infrastructure can serve both markets, with the distinction made when the customer completes the transaction.

Nevada went further. In 2023, the state eliminated separate medical licensing and created a single cannabis establishment license covering cultivation, production and retail activity. State law now prevents the regulator from issuing a new medical-only license.

That raises a practical federal question: how will the DEA identify which inventory, facility, or transaction belongs inside the Schedule III medical lane when state law intentionally merged medical and adult-use operations?

The answer may require statutory amendments—but Nevada’s legislature meets only once every two years. Even a relatively technical licensing correction could therefore become a lengthy political and administrative process.

“More questions than answers,” Klimas said, describing the uncertainty facing mature state markets.

Medical-only states may have a more seamless transition. Dual-use states, by contrast, may need to reconsider inventory separation, licensing categories, recordkeeping, and the point at which a product legally becomes medical.

Schedule III Does Not Finish The Job

Rescheduling recognizes medical use and changes federal tax treatment, but it does not federally legalize cannabis.

That leaves several business problems unresolved, including banking, exchange access, and legal exposure for companies that serve plant-touching operators.

Mangone pointed to continued congressional interest in banking reform and the CLIMB Act, which would create a safe harbor for cannabis companies seeking to list on major U.S. stock exchanges. The legislation would also protect ancillary businesses receiving payment from cannabis operators.

That universe extends far beyond dispensaries and cultivators. It includes real estate professionals, brokers, consultants, contractors, HVAC installers, and other service providers who could otherwise face money-laundering concerns because their customers handle federally controlled products.

Mangone argued that rescheduling may make incremental legislation more politically viable, particularly among Republicans who were previously reluctant to support cannabis reform.

The administration’s decision divided the Republican conference. Some lawmakers opposed rescheduling, while others praised it as overdue. Members entering competitive midterm races may now be less willing to publicly oppose a policy supported by their party’s president.

“The door is open for reform,” Mangone said. “But it’s incumbent on us and the people in this room to keep reminding Congress that the job is not done with rescheduling.”

His warning was equally clear:

“It is only the beginning, and there are still a lot of aspects that need to be addressed that can only be addressed through congressional action rather than administrative action.”

The Hemp Door May Be Closing

The panel also examined the approaching federal restrictions on intoxicating hemp products, scheduled for enforcement on November 12.

Galoob described affected products as “future marijuana”—items that may soon need to enter regulated cannabis channels rather than remain in convenience stores, smoke shops or general retail.

Mangone was skeptical that Congress would reverse course in the near term.

He noted that 76 senators supported the legislation changing the federal hemp definition, while only Sens. Rand Paul and Ted Cruz spoke in favor of an amendment that would have preserved the existing framework.

The vote was not necessarily a clean referendum on hemp policy. Personal and political relationships also matter in the Senate. But the margin demonstrated how difficult reopening the issue would be.

Mangone also identified two political obstacles.

First, former Senate leader Mitch McConnell remained influential and was reportedly telling colleagues that he did not want intoxicating hemp products to become part of his legislative legacy.

Second, Rep. Andy Harris retained considerable power in the House through his committee roles and leadership of the House Freedom Caucus. An effort to reverse the hemp restrictions could cost Speaker Mike Johnson between 20 and 30 Republican votes, forcing him to seek Democratic support for legislation he would not be required to bring forward.

“For right now, Congress has been very definitive that the loophole has been closed, and they intend to keep it that way,” Mangone said.

The political landscape could change in the next Congress, particularly after McConnell’s departure. But operators should not build near-term business plans around the assumption that lawmakers will delay or reverse the restrictions.

What Changes Operationally Right Now?

Despite the significance of Schedule III, Klimas said the immediate day-to-day changes for most licensees would be limited until agencies issue additional guidance.

“Operationally, in the near term, not a lot changes.”

The major immediate financial change is Section 280E. Because the provision applies to trafficking in Schedule I and II substances, moving qualifying medical cannabis to Schedule III could remove that federal tax burden from businesses operating inside the medical framework.

But implementation still raises questions.

The order reportedly contemplates a structure involving the DEA as a nominal purchaser and reseller. Exactly how that mechanism would work—and how it would interact with state supply chains—remains unclear.

Treasury and IRS guidance will also be critical. Operators need to know which revenues, costs, and entities qualify for new tax treatment, particularly when companies share facilities, employees, inventory, or overhead between medical and adult-use operations.

Klimas urged companies to prepare by keeping their books and documentation exceptionally clean.

That includes:

1. Separating medical and adult-use revenue where possible.
2. Documenting inventory movement and points of sale.
3. Reviewing entity structures and intercompany transactions.
4. Confirming that licenses remain valid and accurately categorized.
5. Preparing for possible DEA registration or reporting requirements.
6. Working with qualified tax, legal, and compliance professionals before claiming new treatment.

For now, operators face a period of “listening and waiting,” he said. But waiting should not mean doing nothing.

Litigation Remains A Dark Cloud

The panel also highlighted litigation pending before the U.S. Court of Appeals for the D.C. Circuit.

Several challenges were consolidated into one proceeding. Among the parties were state attorneys general from Nebraska and Indiana, whose participation could strengthen the challengers’ standing arguments.

The litigation may move more slowly than the administrative hearing, but it could ultimately determine whether the federal order survives judicial review.

The panel identified two administrative milestones: the Justice Department’s selection of interested parties for the DEA hearing and the government’s response to a requested judicial stay.

Mangone predicted that the government could seek dismissal of the court challenge while allowing the administrative law judge process to continue. He explicitly framed that as a forecast rather than a certainty.

The administrative hearing, Treasury guidance, and the consolidated litigation therefore form three parallel processes that executives must monitor:

1. DEA rulemaking and evidentiary hearings
2. IRS and Treasury implementation guidance
3. Judicial review in the D.C. Circuit

A favorable development in one does not automatically resolve the others.

The Executive Checklist After Schedule III

The panel did not present Schedule III as a finish line. It presented it as the beginning of a complex implementation period.

Executives should now be preparing for five practical realities:

1. Tax treatment may improve before operations change. The 280E benefit could be immediate for qualifying medical activity, but companies need defensible accounting and legal analysis.
2. State structures may not fit federal categories. Combined licenses, shared inventory, and dual-use facilities could require new tracking systems or legislative changes.
3. Federal guidance will determine execution. DEA, Treasury, and IRS decisions will shape registration, taxation, documentation, and product movement.
4. Congress still controls major reforms. Banking protection, exchange access, and ancillary-business safeguards require legislation.
5. Litigation could alter the timeline. Operators should prepare for implementation while recognizing that courts may modify or delay parts of the framework.

The panel’s clearest takeaway came from Mangone:

“Rescheduling is only the beginning.”

For cannabis executives, the day after Schedule III is not a moment to declare victory. It is the moment to strengthen financial reporting, examine licensing structures, separate business lines, and prepare for the federal bureaucracy that comes next.

As federal cannabis policy continues to evolve, conversations like these will remain essential for operators, investors, regulators, and policymakers alike. IgniteIt’s Cannabis Capital Conference returns to Washington, D.C., on November 18, bringing together the executives, attorneys, lobbyists, regulators, and government affairs leaders shaping the next phase of federal cannabis reform. See you there?